Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART).
Journal
The New England journal of medicine
ISSN: 1533-4406
Titre abrégé: N Engl J Med
Pays: United States
ID NLM: 0255562
Informations de publication
Date de publication:
18 07 2019
18 07 2019
Historique:
entrez:
18
7
2019
pubmed:
18
7
2019
medline:
28
7
2019
Statut:
ppublish
Résumé
A universal testing and treatment strategy is a potential approach to reduce the incidence of human immunodeficiency virus (HIV) infection, yet previous trial results are inconsistent. In the HPTN 071 (PopART) community-randomized trial conducted from 2013 through 2018, we randomly assigned 21 communities in Zambia and South Africa (total population, approximately 1 million) to group A (combination prevention intervention with universal antiretroviral therapy [ART]), group B (the prevention intervention with ART provided according to local guidelines [universal since 2016]), or group C (standard care). The prevention intervention included home-based HIV testing delivered by community workers, who also supported linkage to HIV care and ART adherence. The primary outcome, HIV incidence between months 12 and 36, was measured in a population cohort of approximately 2000 randomly sampled adults (18 to 44 years of age) per community. Viral suppression (<400 copies of HIV RNA per milliliter) was assessed in all HIV-positive participants at 24 months. The population cohort included 48,301 participants. Baseline HIV prevalence was 21% or 22% in each group. Between months 12 and 36, a total of 553 new HIV infections were observed during 39,702 person-years (1.4 per 100 person-years; women, 1.7; men, 0.8). The adjusted rate ratio for group A as compared with group C was 0.93 (95% confidence interval [CI], 0.74 to 1.18; P = 0.51) and for group B as compared with group C was 0.70 (95% CI, 0.55 to 0.88; P = 0.006). The percentage of HIV-positive participants with viral suppression at 24 months was 71.9% in group A, 67.5% in group B, and 60.2% in group C. The estimated percentage of HIV-positive adults in the community who were receiving ART at 36 months was 81% in group A and 80% in group B. A combination prevention intervention with ART provided according to local guidelines resulted in a 30% lower incidence of HIV infection than standard care. The lack of effect with universal ART was unanticipated and not consistent with the data on viral suppression. In this trial setting, universal testing and treatment reduced the population-level incidence of HIV infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; HPTN 071 [PopArt] ClinicalTrials.gov number, NCT01900977.).
Sections du résumé
BACKGROUND
A universal testing and treatment strategy is a potential approach to reduce the incidence of human immunodeficiency virus (HIV) infection, yet previous trial results are inconsistent.
METHODS
In the HPTN 071 (PopART) community-randomized trial conducted from 2013 through 2018, we randomly assigned 21 communities in Zambia and South Africa (total population, approximately 1 million) to group A (combination prevention intervention with universal antiretroviral therapy [ART]), group B (the prevention intervention with ART provided according to local guidelines [universal since 2016]), or group C (standard care). The prevention intervention included home-based HIV testing delivered by community workers, who also supported linkage to HIV care and ART adherence. The primary outcome, HIV incidence between months 12 and 36, was measured in a population cohort of approximately 2000 randomly sampled adults (18 to 44 years of age) per community. Viral suppression (<400 copies of HIV RNA per milliliter) was assessed in all HIV-positive participants at 24 months.
RESULTS
The population cohort included 48,301 participants. Baseline HIV prevalence was 21% or 22% in each group. Between months 12 and 36, a total of 553 new HIV infections were observed during 39,702 person-years (1.4 per 100 person-years; women, 1.7; men, 0.8). The adjusted rate ratio for group A as compared with group C was 0.93 (95% confidence interval [CI], 0.74 to 1.18; P = 0.51) and for group B as compared with group C was 0.70 (95% CI, 0.55 to 0.88; P = 0.006). The percentage of HIV-positive participants with viral suppression at 24 months was 71.9% in group A, 67.5% in group B, and 60.2% in group C. The estimated percentage of HIV-positive adults in the community who were receiving ART at 36 months was 81% in group A and 80% in group B.
CONCLUSIONS
A combination prevention intervention with ART provided according to local guidelines resulted in a 30% lower incidence of HIV infection than standard care. The lack of effect with universal ART was unanticipated and not consistent with the data on viral suppression. In this trial setting, universal testing and treatment reduced the population-level incidence of HIV infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; HPTN 071 [PopArt] ClinicalTrials.gov number, NCT01900977.).
Identifiants
pubmed: 31314965
doi: 10.1056/NEJMoa1814556
pmc: PMC6587177
doi:
Substances chimiques
Anti-Retroviral Agents
0
Banques de données
ClinicalTrials.gov
['NCT01900977']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
207-218Subventions
Organisme : NCRR NIH HHS
ID : R25 RR015600
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068613
Pays : United States
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : UM1 AI068617
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068619
Pays : United States
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019 Massachusetts Medical Society.
Références
Lancet. 2009 Jan 3;373(9657):48-57
pubmed: 19038438
J Int AIDS Soc. 2010 Jan 12;13:1
pubmed: 20205768
Curr Opin HIV AIDS. 2010 Jul;5(4):298-304
pubmed: 20543604
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
PLoS Med. 2012;9(7):e1001245
pubmed: 22802730
Lancet Infect Dis. 2013 Jan;13(1):65-76
pubmed: 23257232
Science. 2013 Feb 22;339(6122):966-71
pubmed: 23430656
PLoS One. 2014 Jan 15;9(1):e84511
pubmed: 24454728
Trials. 2014 Feb 13;15:57
pubmed: 24524229
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
N Engl J Med. 2015 Aug 27;373(9):808-22
pubmed: 26193126
Lancet HIV. 2016 Jul;3(7):e307-17
pubmed: 27365205
Lancet HIV. 2016 Jul;3(7):e318-22
pubmed: 27365206
JAMA. 2016 Jul 12;316(2):171-81
pubmed: 27404185
N Engl J Med. 2016 Sep 1;375(9):830-9
pubmed: 27424812
PLoS Med. 2017 May 2;14(5):e1002292
pubmed: 28464041
Lancet HIV. 2018 Mar;5(3):e116-e125
pubmed: 29199100
Sci Transl Med. 2017 Dec 13;9(420):null
pubmed: 29237762
N Engl J Med. 2018 May 17;378(20):1859-1861
pubmed: 29768142
PLoS One. 2018 Aug 10;13(8):e0197904
pubmed: 30096139
J Acquir Immune Defic Syndr. 2019 Jan 1;80(1):56-63
pubmed: 30399035
JAMA. 2019 Feb 5;321(5):451-452
pubmed: 30629090
AIDS. 2019 Jun 1;33(7):1241-1246
pubmed: 30649065